pindolol has been researched along with Centriacinar Emphysema in 2 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trauth, HA | 1 |
| Sentissi, M | 1 |
| Schrijen, F | 1 |
| Sadoul, P | 1 |
2 other studies available for pindolol and Centriacinar Emphysema
| Article | Year |
|---|---|
[Antihypertensive treatment with beta receptor blockers and obstructive ventilatory disorder (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Bronchitis; Dose-Response Relationship, Drug; Female; Humans; Hy | 1981 |
[Hemodynamic effects of practolol in chronic bronchopneumopathies].
Topics: Adult; Asthma; Bronchitis; Cardiac Volume; Chronic Disease; Drug Evaluation; Heart Rate; Hemodynamic | 1974 |